Banking and Distribution of Large Cryopreserved Arterial Homografts in Brussels: Assessment of 4 Years of Activity by the European Homograft Bank (EHB) with Reference to Implantation Results in Reconstruction of Infected Infrarenal Arterial Prostheses and Mycotic Aneurysms

Abstract

In 1991 European Homograft Bank (EHB) initiated a program of cryopreservation and distribution of large arteries to meet a new demand for quality-controlled arterial homo grafts of various sizes. From May 1991 to June 1995, 308 arteries have been registered from 136 donors: 122 brain death cases and 14 cadavers (mean age 34 years, male/female ratio 1.52/1); 263 arteries were cryopreserved (113 aortas, 64 aortic bifur cations, and 86 femoral); 19 were discarded for atherosclerosis (6.7%); 10 batches of arteries were partially or totally discarded because of persistent contamination and further eight batches for positive or doubtful viral serology. One hundred patients were treated in nine European centers with one (N = 69) or more EHB homografts. Indications were: infected prosthesis 70 (17 with aortoenteric fistula); mycotic aneurysm 19 (four ascending aortas, two with bronchial fistula); neoplastic infiltration of subrenal aorta one; extracardiac reconstructions/shunts 10. (continued on next page) (Abstract continued) Results from homograft reconstructions in infected prosthesis or mycotic aneurysm were available in 90 patients. There were 19 early deaths and 24 early complications, three were directly graft-related and included a fatal case of homograft rupture. Sixty- seven vascular cases were followed up from 1 month onward (mean: 16 months): 50 were uneventful; there were nine late deaths, of which two resulted from graft-related digestive hemorrhage; there were eight cases of late complications; three arteries were partly explanted as a result of focal thrombosis. Four patients were lost to follow-up. In the cases of aortoenteric fistula, however, the results were disappointing with only five late survivors of the 16 treated patients. Finally, these results show that cryopreserved arteries seem to perform as well in the midterm as the fresh ones.

Both the banking activity of cryopreserved homografts and the short- to mid-term performances of the implants in cases of prosthetic or native arterial infection are very satisfactory, provided no aortoenteric fistula is present. Cryopreserved arteries can also be used for extracardiac shunts and reconstructions.

Get full access to this article

View all access options for this article.

References

Gross RE , Huwitt ES , Bill AH Jr, et al: Preliminary observations on the use of human arterial grafts in the treatment of certain cardiovascular defects. N Engl J Med 239:578-579, 1948.

Oudot J. : Greffe de la bifurcation aortique depuis les artères renales jusqu'aux artères iliaques externes pour thrombose artéritique. Mem Acad Chir (Paris) 77:642-644, 1951.

Dubost C. , Allary M. , Oeconomos N. : A propos du traitement des anévrysmes de l'aorte—ablation de l'anévrysme: rétablissement de la continuité par greffe de l'aorte humaine conservée. Mem Acad Chir (Paris) 77:381-383, 1951.

De Bakey ME , Creech O Jr: Occlusive disease of the aorta and its treatment by resection and homograft replacement. Ann Surg 140:290-310, 1954.

Szilagyi DE , Overhulse PR , Logrippo GA : Use of chemically sterilized arterial homografts. Clin Res Proc 2:108-113, 1954.

Halpert B. , De Bakey ME , Jordan GL , et al: The fate of homografts and prostheses of the human aorta. Surg Gynecol Obstet 111:659-674, 1960.

Szilagyi DE , Rodriguez FJ , Smith RF , et al: Late fate of arterial allografts. Observations 6 to 15 years after implantation. Arch Surg 101:721-733, 1970.

Kieffer E. , Bahnini A. , Koskas F. , et al: In situ allograft replacement of infected infrarenal aortic prosthetic grafts: Results in forty-three patients. J Vasc Surg 17: 349-356, 1993.

Dinis da Gama A. , Sarmento C. , Vieira T. , et al: The use of cryopreserved arterial allografts for vascular reconstruction in patients receiving immunosuppression for organ transplantation. J Vasc Surg 20:271-278, 1994.

10.

Nevelsteen A. , Goffin Y. , Lacroix H. , et al: Recurrent aortic infection: Treatment by arterial homograft replacement. Cardiovasc Surg 3:441-444, 1995.

11.

Vogt PR , von Segesser LK , Goffin Y. , et al: Cryopreserved arterial homografts for in situ reconstruction of mycotic aneurysms and prosthetic graft infection. Eur J Cardiothorac Surg 9:502-506, 1995.

12.

Goffin YA , Van Hoeck B : The European Homograft Bank (EHB) International Association: Assessment of its 3 years operation as a non-profit-making organization for the banking and distribution of cryopreserved cardiovascular tissues. ETCO Newsletter 10(2):4-9, 1992.

13.

Goffin YA : Contrôle de qualité des Allogreffes valvulaires cryopréservées. In: Allogreffes et Autogreffes valvulaires cardiaques, ed. 1, ed. by Metras D. Paris: Masson, 1995, pp 16-22.

14.

Strickett MG , Barratt-Boyes BG, McCulloch D: Disinfection of human heart allografts with antibiotics in low concentration. Pathology 15:457-462, 1983.

15.

Neves J. , Monteiro C. , Santos R. , et al: Histologic and genetic assessment of explanted allograft valves . VI International Symposium for Cardiac Bioprostheses . Ann Thorac Surg 2 (suppl):141-145, 1995.

16.

Fischlein T. , Schütz A. , Haushofer M. , et al: Immunologic reaction and viability of cryopreserved homografts. VI International Symposium for Cardiac Bioprostheses. Ann Thorac Surg 2 (suppl):122-126, 1995.

17.

Smith JD , Ogino H. , Hunt D. , et al: Humoral immune response to human aortic valve homografts. VI International Symposium for Cardiac Bioprostheses. Ann Thorac Surg 2 (suppl):127-130, 1995.